Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Walleye Capital LLC

Walleye Capital LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 831.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 364,750 shares of the company's stock after purchasing an additional 325,585 shares during the quarter. Walleye Capital LLC owned approximately 0.43% of Syndax Pharmaceuticals worth $4,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNDX. Barclays PLC grew its holdings in Syndax Pharmaceuticals by 4.5% during the fourth quarter. Barclays PLC now owns 196,051 shares of the company's stock valued at $2,592,000 after purchasing an additional 8,422 shares during the period. Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals during the fourth quarter worth approximately $152,000. Renaissance Technologies LLC acquired a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $9,002,000. Aristides Capital LLC acquired a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $197,000. Finally, Russell Investments Group Ltd. boosted its stake in Syndax Pharmaceuticals by 114.8% in the 4th quarter. Russell Investments Group Ltd. now owns 29,022 shares of the company's stock valued at $384,000 after purchasing an additional 15,508 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SNDX. HC Wainwright restated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. Citigroup dropped their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. Finally, Scotiabank decreased their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $36.20.

Insider Transactions at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares of the company's stock, valued at $1,406,563. The trade was a 4.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX traded up $0.58 during trading on Tuesday, reaching $12.51. 304,987 shares of the company's stock traded hands, compared to its average volume of 1,582,091. The company's 50 day simple moving average is $13.22 and its two-hundred day simple moving average is $14.99. Syndax Pharmaceuticals, Inc. has a 12-month low of $9.66 and a 12-month high of $25.07. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -3.43 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).